Addressing global mental health is a major 21st-century challenge. Current treatments have recognized limitations; in this context, new ones that are prophylactic and effective across diagnostic boundaries would represent a major advance. The view that there exists a core of transdiagnostic overlap between psychiatric disorders has re-emerged in recent years, and evidence that psychedelic therapy holds promise for a range of psychiatric disorders supports the position that it may be transdiagnostically effective. Here, we propose that psychedelic therapy's core, transdiagnostically relevant action lies in its ability to increase neuronal and mental plasticity, thus enhancing the potential for change, which we consider to be a key to its therapeutic benefits. Moreover, we suggest that enhanced plasticity via psychedelics, combined with a psychotherapeutic approach, can aid healthy adaptability and resilience, which are protective factors for long-term well-being. We present candidate neurological and psychological markers of this plasticity and link them with a predictive processing model of the action of psychedelics. We propose that a model of psychedelic-induced plasticity combined with an adequate therapeutic context has prophylactic and transdiagnostic potential, implying that it could have a broad, positive impact on public health.

3rd Faculty of Medicine Charles University Prague Czechia

Beyond Psychedelics Prague Czechia

Centre for Psychedelic Research Imperial College London London United Kingdom

Department of Applied Neuroscience and Neuroimaging National Institute of Mental Health Klecany Czechia

Department of Psychology Faculty of Arts Charles University Prague Czechia

Department of Translational Neuroscience National Institute of Mental Health Klecany Czechia

See more in PubMed

Oxford English Dictionary Online (2020) . Available online at: https://www.lexico.com/definition/plasticity (accessed June 4, 2021).

Haslam N, Mcgrath MJ, Viechtbauer W, Kuppens P. Dimensions over categories: a meta-analysis of taxometric research. Psychol Med. (2020) 50:1418–32. 10.1017/S003329172000183X PubMed DOI

Syme KL, Hagen EH. Mental health is biological health: Why tackling “diseases of the mind” is an imperative for biological anthropology in the 21st century. Am J Phys Anthropol. (2020) 171:87–117. 10.10022/ajpa.23965 PubMed DOI

WHO (2017). Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization.

WHO (2004). Prevention of Mental Disorders: effective Interventions and Policy Options: Summary Report/a Report of the World Health Organization Dept. of Mental Health and Substance Abuse; in collaboration with the Prevention Research Centre of the Universities of Nijmegen and Maastricht. World Health Organization,.

Wainberg ML, Scorza P, Shultz JM, Helpman L, Mootz JJ, Johnson KA, et al. . Challenges and opportunities in global mental health: a research-to-practice perspective. Curr Psychiatry Rep. (2017) 19:28. 10.1007/s11920-017-0780-z PubMed DOI PMC

Van Gerven J, Cohen A. Vanishing clinical psychopharmacology. Br J Clin Pharmacol. (2011) 72:1–5. 10.1111/j.1365-2125.2011.04021.x PubMed DOI PMC

Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, et al. . Adverse reactions to antidepressants. Br J Psychiatry. (2009) 195:202–10. 10.1192/bjp.bp.108.061960 PubMed DOI

Barbui C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ. (2008) 178:296–305. 10.1503/cmaj.070693 PubMed DOI PMC

Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. (2012) 6:369. 10.2147/PPA.S29716 PubMed DOI PMC

Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. . Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Focus. (2018) 16:420–9. 10.1176/appi.focus.16407 PubMed DOI PMC

Rush AJ, South C, Jha MK, Jain SB, Trivedi MH. What to expect when switching to a second antidepressant medication following an ineffective initial SSRI: a report from the randomized clinical STAR* D study. J Clin Psychiatry. (2020) 81:19m12949. 10.4088/JCP.19m12949 PubMed DOI

Mchugh RK, Whitton SW, Peckham AD, Welge JA, Otto MW. Patient preference for psychological vs. pharmacological treatment of psychiatric disorders: a meta-analytic review. J Clin Psychiatry. (2013) 74:595. 10.4088/JCP.12r07757 PubMed DOI PMC

Thase ME, Friedman ES. Is psychotherapy an effective treatment for melancholia and other severe depressive states? J Affect Disord. (1999) 54:1–19. 10.1016/S0165-0327(99)00033-6 PubMed DOI

Min J-A, Lee C-U, Lee C. Mental health promotion and illness prevention: a challenge for psychiatrists. Psychiatry Investig. (2013) 10:307–16. 10.4306/pi.2013.10.4.307 PubMed DOI PMC

Varese F, Smeets F, Drukker M, Lieverse R, Lataster T, Viechtbauer W, et al. . Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective-and cross-sectional cohort studies. Schizophr Bull. (2012) 38:661–71. 10.1093/schbul/sbs050 PubMed DOI PMC

Felitti VJ, Anda RF. The relationship of adverse childhood experiences to adult medical disease, psychiatric disorders, and sexual behavior: Implications for healthcare. In: Ruth A L, Eric V, Clare P, editors. The Impact of Early Life Trauma on Health and Disease: The Hidden Epidemic. Cambridge: Cambridge University Press; (2010). p. 77–87.

Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, Duncan L, et al. . Analysis of shared heritability in common disorders of the brain. Science. (2018) 360:eaap8757. 10.1126/science.aap8757 PubMed DOI PMC

Brouwer A, Carhart-Harris RL. Pivotal mental states. J Psychopharmacol. (2020) 35:319–52. 10.1177/0269881120959637 PubMed DOI PMC

Werner E. Resilience and recovery: findings from the Kauai longitudinal study. Res Policy Pract Childrens Mental Health. (2005) 19:11–4.

Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry. (2010) 167:509–27. 10.1176/appi.ajp.2010.09101452 PubMed DOI PMC

Carhart-Harris RL. Serotonin, psychedelics and psychiatry. World Psychiatry. (2018) 17:358. 10.1002/wps.20555 PubMed DOI PMC

Miyazaki K, Miyazaki KW, Doya K. The role of serotonin in the regulation of patience and impulsivity. Mol Neurobiol. (2012) 45:213–24. 10.1007/s12035-012-8232-6 PubMed DOI PMC

Campbell-Sills L, Forde DR, Stein MB. Demographic and childhood environmental predictors of resilience in a community sample. J Psychiatr Res. (2009) 43:1007–12. 10.1016/j.jpsychires.2009.01.013 PubMed DOI

Davydov DM, Stewart R, Ritchie K, Chaudieu I. Resilience and mental health. Clin Psychol Rev. (2010) 30:479–95. 10.1016/j.cpr.2010.03.003 PubMed DOI

Coie JD, Watt NF, West SG, Hawkins JD, Asarnow JR, Markman HJ, et al. . The science of prevention: A conceptual framework and some directions for a national research program. Am Psychol. (1993) 48:1013–22. 10.1037/0003-066X.48.10.1013 PubMed DOI

Waddington CH. Canalization of development and genetic assimilation of acquired characters. Nature. (1959) 183:1654–5. 10.1038/1831654a0 PubMed DOI

Carhart-Harris RL. How do psychedelics work? Curr Opin Psychiatry. (2019) 32:16–21. 10.1097/YCO.0000000000000467 PubMed DOI

Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, et al. . Psychedelics and the essential importance of context. J Psychopharmacol. (2018) 32:725–31. 10.1177/0269881118754710 PubMed DOI

Sauer-Zavala S, Gutner CA, Farchione TJ, Boettcher HT, Bullis JR, Barlow DH. Current definitions of “transdiagnostic” in treatment development: a search for consensus. Behav Ther. (2017) 48:128–38. 10.1016/j.beth.2016.09.004 PubMed DOI

Dozois DJ, Seeds PM, Collins KA. Transdiagnostic approaches to the prevention of depression and anxiety. J Cogn Psychother. (2009) 23:44. 10.1891/0889-8391.23.1.44 DOI

Lai HMX, Cleary M, Sitharthan T, Hunt GE. Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990–2014: a systematic review and meta-analysis. Drug Alcohol Depend. (2015) 154:1–13. 10.1016/j.drugalcdep.2015.05.031 PubMed DOI

Kessler RC, Sampson NA, Berglund P, Gruber M, Al-Hamzawi A, Andrade L, et al. . Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiol Psychiatr Sci. (2015) 24:210–26. 10.1017/S2045796015000189 PubMed DOI PMC

Dean CE. Whither research domain criteria? J Nerv Ment Dis. (2019) 207:419–20. 10.1097/NMD.0000000000000985 PubMed DOI

Hofmann SG, Hayes SC. The future of intervention science: process-based therapy. Clin Psychol Sci. (2019) 7:37–50. 10.1177/2167702618772296 PubMed DOI PMC

Hayes SC, Hofmann SG. The third wave of cognitive behavioral therapy and the rise of process-based care. World Psychiatry. (2017) 16:245. 10.1002/wps.20442 PubMed DOI PMC

Hentschel U, Draguns JG, Ehlers W, Smith G. editors. Defense Mechanisms: Current Approaches to Research and Measurement. In: Defense Mechanisms: Theoretical, Research and Clinical Perspectives. Elsevier Science Ltd; (2004). p. 3–41. 10.1016/S0166-4115(04)80026-8 DOI

Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. (2015) 7:157–64. 10.2174/1874473708666150107121331 PubMed DOI PMC

Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. (2015) 29:289–99. 10.1177/0269881114565144 PubMed DOI

Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. (2006) 67:1735–40. 10.4088/JCP.v67n1110 PubMed DOI

Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, et al. . Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. (2016) 3:619–27. 10.1016/S2215-0366(16)30065-7 PubMed DOI

Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. . Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. (2018) 49:655–63. 10.1017/S0033291718001356 PubMed DOI PMC

Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. . Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. (2020) 78:481–9. 10.1001/jamapsychiatry.2020.3285 PubMed DOI PMC

Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. . Trial of psilocybin versus escitalopram for depression. New Engl J Med. (2021) 384:1402–11. 10.1056/NEJMoa2032994 PubMed DOI

Grob CS, Danforth AL, Chopra GS, Hagerty M, Mckay CR, Halberstadt AL, et al. . Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. (2011) 68:71–8. 10.1001/archgenpsychiatry.2010.116 PubMed DOI

Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. . Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. (2014) 202:513–20. 10.1097/NMD.0000000000000113 PubMed DOI PMC

Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. . Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. (2016) 30:1165–80. 10.1177/0269881116675512 PubMed DOI PMC

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. . Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. (2016) 30:1181–97. 10.1177/0269881116675513 PubMed DOI PMC

Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. . Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. (2020) 177:391–410. 10.1176/appi.ajp.2019.19010035 PubMed DOI

Butler M, Seynaeve M, Nicholson TR, Pick S, Kanaan RA, Lees A, et al. . Psychedelic treatment of functional neurological disorder: a systematic review. Ther Adv Psychopharmacol. (2020) 10:2045125320912125. 10.1177/2045125320912125 PubMed DOI PMC

Renelli M, Fletcher J, Tupper KW, Files N, Loizaga-Velder A, Lafrance A. An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders. Eating Weight Disord Stud Anorexia Bulimia Obes. (2018) 25:437–44. 10.1007/s40519-018-0619-6 PubMed DOI

Spriggs MJ, Kettner H, Carhart-Harris RL. Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. Eat Weight Disord. (2020) 26:1265–70. 10.1007/s40519-020-01000-8 PubMed DOI

Ramachandran V, Chunharas C, Marcus Z, Furnish T, Lin A. Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF). Neurocase. (2018) 24:105–10. 10.1080/13554794.2018.1468469 PubMed DOI

Hausner M, Segal E. LSD: The Highway to Mental Health. ASC Books; (2009).

Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of±3, 4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. (2011) 25:439–52. 10.1177/0269881110378371 PubMed DOI PMC

Nielson JL, Megler JD. Ayahuasca as a candidate therapy for PTSD. In: The Therapeutic Use of Ayahuasca. Berlin; Heidelberg: Springer; (2014). p. 41–58.

Ossebaard H, Maalsté N. (1999). The Bastiaans method of drug-assisted therapy. a preliminary follow-up study with former clients. Zugriff am. 7:2013.

Winkler P, Gorman I, Kočárová R. Use of LSD by mental health professionals. In: Preedy VR, editor. Neuropathology of Drug Addictions and Substance Misuse: Stimulants, Club and Dissociative Drugs, Hallucinogens, Steroids, Inhalants and International Aspects. London; San Diego; Cambridge; Oxford: Academic Press; (2016).

Winkler P, Kočárová R. Psychedelic treatment of disruptive personality patterns. In: Michael JW, Ben S, editors. Advances in Psychedelic Medicine: State-of-the-Art Therapeutic Applications. Santa Barbara, CA; Denver, CO: Praeger; (2019). p. 232.

Zeifman RJ, Wagner AC. Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder. J Contextual Behav Sci. (2020) 15:1–11. 10.1016/j.jcbs.2019.11.001 DOI

Van Mulukom V, Patterson R, Van Elk M. Broadening your mind to include others: The relationship between serotonergic psychedelic experiences and maladaptive narcissism. Psychopharmacology. (2020) 237:2725–37. PubMed

Carhart-Harris R, Friston K. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev. (2019) 71:316–44. 10.1124/pr.118.017160 PubMed DOI PMC

Johansen P-Ø, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol. (2015) 29:270–9. 10.1177/0269881114568039 PubMed DOI

Krebs TS, Johansen PO. Psychedelics and mental health: a population study. PLoS ONE. (2013) 8:e63972. 10.1371/journal.pone.0063972 PubMed DOI PMC

Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol. (2015) 29:280–8. 10.1177/0269881114565653 PubMed DOI

Zeifman RJ, Wagner AC, Watts R, Kettner H, Mertens LJ, Carhart-Harris RL. Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation. Front Psychiatry. (2020) 11:782. 10.3389/fpsyt.2020.00782 PubMed DOI PMC

Argento E, Braschel M, Walsh Z, Socias ME, Shannon K. The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women. J Psychopharmacol. (2018) 32:1385–91. 10.1177/0269881118798610 PubMed DOI PMC

Argento E, Strathdee SA, Tupper K, Braschel M, Wood E, Shannon K. Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting. BMJ Open. (2017) 7:e016025. 10.1136/bmjopen-2017-016025 PubMed DOI PMC

Carhart-Harris R, Bolstridge M, Day C, Rucker J, Watts R, Erritzoe D, et al. . Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. (2018) 235:399–408. 10.1007/s00213-017-4771-x PubMed DOI PMC

Zeifman R, Palhano-Fontes F, Hallak J, Nunes EA, Maia-De-Oliveira JP, De Araujo DB. The impact of ayahuasca on suicidality: results from a randomized controlled trial. Front Pharmacol. (2019) 10:1325. 10.3389/fphar.2019.01325 PubMed DOI PMC

Halpern JH, Sherwood AR, Hudson JI, Yurgelun-Todd D, Pope HG Jr. Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry. (2005) 58:624–31. 10.1016/j.biopsych.2005.06.038 PubMed DOI

Bouso JC, González D, Fondevila S, Cutchet M, Fernández X, Barbosa PCR, et al. . Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: a longitudinal study. PLoS ONE. (2012) 7:e42421. 10.1371/journal.pone.0042421 PubMed DOI PMC

Jungaberle H, Thal S, Zeuch A, Rougemont-Bücking A, Von Heyden M, Aicher H, et al. . Positive psychology in the investigation of psychedelics and entactogens: a critical review. Neuropharmacology. (2018) 142:179–99. 10.1016/j.neuropharm.2018.06.034 PubMed DOI

Griffiths RR, Johnson MW, Richards WA, Richards BD, Jesse R, Maclean KA, et al. . Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol. (2018) 32:49–69. 10.1177/0269881117731279 PubMed DOI PMC

Lyons T, Carhart-Harris RL. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. J Psychopharmacol. (2018) 32:811–9. 10.1177/0269881117748902 PubMed DOI PMC

Kettner H, Gandy S, Haijen EC, Carhart-Harris RL. From egoism to ecoism: psychedelics increase nature relatedness in a state-mediated and context-dependent manner. Int J Environ Res Public Health. (2019) 16:5147. 10.3390/ijerph16245147 PubMed DOI PMC

Bouso JC, Dos Santos RG, Alcázar-Córcoles MÁ, Hallak JE. Serotonergic psychedelics and personality: a systematic review of contemporary research. Neurosci Biobehav Rev. (2018) 87:118–32. 10.1016/j.neubiorev.2018.02.004 PubMed DOI

MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. (2011) 25:1453–61. 10.1177/0269881111420188 PubMed DOI PMC

Close JB, Hajien EC, Watts R, Roseman L, Carhart-Harris RL. Psychedelics and psychological flexibility–Results of a prospective web-survey using the Acceptance in Action Questionnaire II. J Context Behav Sci. (2020) 16:37–44. 10.1016/j.jcbs.2020.01.005 DOI

Watts R, Luoma J. The use of the psychological flexibility model to support psychedelic assisted therapy. J Contextual Behav Sci. 15:92–102.

Belser AB, Agin-Liebes G, Swift TC, Terrana S, Devenot N, Friedman HL, et al. . Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. J Hum Psychol. (2017) 57:354–88. 10.1177/0022167817706884 DOI

Murphy-Beiner A, Soar K. Ayahuasca's ‘afterglow': improved mindfulness and cognitive flexibility in ayahuasca drinkers. Psychopharmacology. (2020) 237:1161–9. 10.1007/s00213-019-05445-3 PubMed DOI

Boulougouris V, Glennon JC, Robbins TW. Dissociable effects of selective 5-HT 2A and 5-HT 2C receptor antagonists on serial spatial reversal learning in rats. Neuropsychopharmacology. (2008) 33:2007. 10.1038/sj.npp.1301584 PubMed DOI

King A, Martin I, Seymour K. Reversal learning facilitated by a single injection of lysergic acid diethylamide (LSD 25) in the rat. Br J Pharmacol. (1972) 45:161P. PubMed PMC

Domínguez-Clavé E, Soler J, Pascual JC, Elices M, Franquesa A, Valle M, et al. . Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits. Psychopharmacology. (2019) 236:573–80. 10.1007/s00213-018-5085-3 PubMed DOI

Sampedro F, De La Fuente Revenga M, Valle M, Roberto N, Domínguez-Clavé E, Elices M, et al. . Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities. Int J Neuropsychopharmacol. (2017) 20:698–711. 10.1093/ijnp/pyx036 PubMed DOI PMC

Soler J, Elices M, Franquesa A, Barker S, Friedlander P, Feilding A, et al. . Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities. Psychopharmacology. (2016) 233:823–9. 10.1007/s00213-015-4162-0 PubMed DOI

Uthaug M, Van Oorsouw K, Kuypers K, Van Boxtel M, Broers N, Mason N, et al. . Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. Psychopharmacology. (2018) 235:2979–89. 10.1007/s00213-018-4988-3 PubMed DOI PMC

Uthaug M, Lancelotta R, Van Oorsouw K, Kuypers K, Mason N, Rak J, et al. . A single inhalation of vapor from dried toad secretion containing 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology. (2019) 236:2653–66. 10.1007/s00213-019-05236-w PubMed DOI PMC

Brachman RA, Mcgowan JC, Perusini JN, Lim SC, Pham TH, Faye C, et al. . Ketamine as a prophylactic against stress-induced depressive-like behavior. Biol Psychiatry. (2016) 79:776–86. PubMed PMC

Frecska E, Móré CE, Vargha A, Luna LE. Enhancement of creative expression and entoptic phenomena as after-effects of repeated ayahuasca ceremonies. J Psychoactive Drugs. (2012) 44:191–9. 10.1080/02791072.2012.703099 PubMed DOI

Noorani T, Garcia-Romeu A, Swift TC, Griffiths RR, Johnson MW. Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts. J Psychopharmacol. (2018) 32:756–69. PubMed

Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R. Patients' accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. J Hum Psychol. (2017) 57:520–64. 10.1177/0022167817709585 DOI

Catlow BJ, Song S, Paredes DA, Kirstein CL, Sanchez-Ramos J. Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res. (2013) 228:481–91. 10.1007/s00221-013-3579-0 PubMed DOI

Erritzoe D, Roseman L, Nour M, Maclean K, Kaelen M, Nutt D, et al. . Effects of psilocybin therapy on personality structure. Acta Psychiatr Scand. (2018) 138:368–78. 10.1111/acps.12904 PubMed DOI PMC

Levin ME, Hildebrandt MJ, Lillis J, Hayes SC. The impact of treatment components suggested by the psychological flexibility model: a meta-analysis of laboratory-based component studies. Behav Ther. (2012) 43:741–56. 10.1016/j.beth.2012.05.003 PubMed DOI

Mccracken LM, Velleman SC. Psychological flexibility in adults with chronic pain: a study of acceptance, mindfulness, and values-based action in primary care. Pain. (2010) 148:141–7. 10.1016/j.pain.2009.10.034 PubMed DOI

Moore A, Malinowski P. Meditation, mindfulness and cognitive flexibility. Conscious Cogn. (2009) 18:176–86. 10.1016/j.concog.2008.12.008 PubMed DOI

Lebuda I, Zabelina DL, Karwowski M. Mind full of ideas: a meta-analysis of the mindfulness–creativity link. Pers Individ Dif. (2016) 93:22–6. 10.1016/j.paid.2015.09.040 DOI

Tomac MM. The Influence of Mindfulness on Resilience in Context of Attachment Style, Affect Regulation, and Self-Esteem. Washington, DC: Walden University; (2011).

Coffey KA, Hartman M, Fredrickson BL. Deconstructing mindfulness and constructing mental health: understanding mindfulness and its mechanisms of action. Mindfulness. (2010) 1:235–53. 10.1007/s12671-010-0033-2 DOI

Waugh CE, Thompson RJ, Gotlib IH. Flexible emotional responsiveness in trait resilience. Emotion. (2011) 11:1059. PubMed PMC

Harvey JA. Role of the serotonin 5-HT2A receptor in learning. Learn Mem. (2003) 10:355–62. 10.1101/lm.60803 PubMed DOI PMC

Nour MM, Evans L, Nutt D, Carhart-Harris RL. Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI). Front Hum Neurosci. (2016) 10:269. 10.3389/fnhum.2016.00269 PubMed DOI PMC

Timmermann C, Roseman L, Williams L, Erritzoe D, Martial C, Cassol H, et al. . DMT models the near-death experience. Front Psychol. (2018) 9:1424. 10.3389/fpsyg.2018.01424 PubMed DOI PMC

Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R. Emotional breakthrough and psychedelics: validation of the Emotional Breakthrough Inventory. J Psychopharmacol. (2019) 33:1076–87. 10.1177/0269881119855974 PubMed DOI

Breeksema JJ, Niemeijer AR, Krediet E, Vermetten E, Schoevers RA. Psychedelic treatments for psychiatric disorders: a systematic review and thematic synthesis of patient experiences in qualitative studies. CNS Drugs. (2020) 34:925–46. 10.1007/s40263-020-00748-y PubMed DOI PMC

Milliere R. Looking for the self: phenomenology, neurophysiology and philosophical significance of drug-induced ego dissolution. Front Hum Neurosci. (2017) 11:245. 10.3389/fnhum.2017.00245 PubMed DOI PMC

Griffiths RR, Johnson MW, Richards WA, Richards BD, Mccann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology. (2011) 218:649–65. 10.1007/s00213-011-2358-5 PubMed DOI PMC

Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. . Psychedelics promote structural and functional neural plasticity. Cell Rep. (2018) 23:3170–82. 10.1016/j.celrep.2018.05.022 PubMed DOI PMC

Kowiański P, Lietzau G, Czuba E, Waśkow M, Steliga A, Moryś J. BDNF: a key factor with multipotent impact on brain signaling and synaptic plasticity. Cell Mol Neurobiol. (2018) 38:579–93. 10.1007/s10571-017-0510-4 PubMed DOI PMC

Spriggs M, Cadwallader C, Hamm J, Tippett L, Kirk I. Age-related alterations in human neocortical plasticity. Brain Res Bull. (2017) 130:53–9. 10.1016/j.brainresbull.2016.12.015 PubMed DOI

Hayes SC, Strosahl KD, Wilson KG. Acceptance and Commitment Therapy: The Process and Practice of Mindful change. New York, NY: Guilford Press; (2011).

Rolffs JL, Rogge RD, Wilson KG. Disentangling components of flexibility via the hexaflex model: development and validation of the multidimensional psychological flexibility inventory (MPFI). Assessment. (2018) 25:458–82. 10.1177/1073191116645905 PubMed DOI

Luoma JB, Sabucedo P, Eriksson J, Gates N, Pilecki BC. Toward a contextual psychedelic-assisted therapy: perspectives from acceptance and commitment therapy and contextual behavioral science. J Context Behav Sci. (2019) 14:136–45. 10.1016/j.jcbs.2019.10.003 DOI

Levin ME, Maclane C, Daflos S, Seeley JR, Hayes SC, Biglan A, et al. . Examining psychological inflexibility as a transdiagnostic process across psychological disorders. J Context Behav Sci. (2014) 3:155–63. 10.1016/j.jcbs.2014.06.003 PubMed DOI PMC

Meiran N, Diamond GM, Toder D, Nemets B. Cognitive rigidity in unipolar depression and obsessive compulsive disorder: examination of task switching, stroop, working memory updating and post-conflict adaptation. Psychiatry Res. (2011) 185:149–56. 10.1016/j.psychres.2010.04.044 PubMed DOI

Fisher AJ, Newman MG. Reductions in the diurnal rigidity of anxiety predict treatment outcome in cognitive behavioral therapy for generalized anxiety disorder. Behav Res Ther. (2016) 79:46–55. 10.1016/j.brat.2016.02.006 PubMed DOI PMC

Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Ther. (2017) 101:209–19. 10.1002/cpt.557 PubMed DOI

Lafrance A, Loizaga-Velder A, Fletcher J, Renelli M, Files N, Tupper KW. Nourishing the spirit: exploratory research on ayahuasca experiences along the continuum of recovery from eating disorders. J Psychoactive Drugs. (2017) 49:427–35. 10.1080/02791072.2017.1361559 PubMed DOI

Hayes SC. A Liberated Mind: How to Pivot Toward What Matters. New York, NY: Avery; (2019).

Bond FW, Hayes SC, Baer RA, Carpenter KM, Guenole N, Orcutt HK, et al. . Preliminary psychometric properties of the acceptance and action questionnaire–II: a revised measure of psychological inflexibility and experiential avoidance. Behav Ther. (2011) 42:676–88. 10.1016/j.beth.2011.03.007 PubMed DOI

Kashdan TB, Rottenberg J. Psychological flexibility as a fundamental aspect of health. Clin Psychol Rev. (2010) 30:865–78. 10.1016/j.cpr.2010.03.001 PubMed DOI PMC

Fledderus M, Bohlmeijer ET, Smit F, Westerhof GJ. Mental health promotion as a new goal in public mental health care: A randomized controlled trial of an intervention enhancing psychological flexibility. Am J Public Health. (2010) 100:2372. 10.2105/AJPH.2010.196196 PubMed DOI PMC

Hayes SC. Acceptance and commitment therapy, relational frame theory, and the third wave of behavioral and cognitive therapies. Behav Ther. (2004) 35:639–65. 10.1016/S0005-7894(04)80013-3 PubMed DOI

Hofmann SG, Sawyer AT, Fang A. The empirical status of the “new wave” of cognitive behavioral therapy. Psychiatr Clin. (2010) 33:701–10. 10.1016/j.psc.2010.04.006 PubMed DOI PMC

Hanh N. The Miracle of Mindfulness: The Classic Guide to Meditation by the World's Most Revered Master. London: Ebury Digital; (2017).

Wright R. Why Buddhism Is True: The Science and Philosophy of Meditation and Enlightenment. New York, NY: Simon and Schuster; (2017).

Ciarrochi J, Bilich L, Godsell C. Psychological flexibility as a mechanism of change in acceptance and commitment therapy. In: Baer RA, editor. Assessing Mindfulness and Acceptance Processes in Clients: Illuminating the Theory and Practice of Change. Oakland: Context Press/New Harbinger Publications; (2010). p. 51–75.

Kočárová R. Účinné faktory rituálního uŽití ayahuascy pri léčbě závislostí v psychoterapeutickém kontextu (Master). Masaryk University; (2016).

Carhart-Harris RL, Erritzoe D, Haijen E, Kaelen M, Watts R. Psychedelics and connectedness. Psychopharmacology. (2018) 235:547–50. 10.1007/s00213-017-4701-y PubMed DOI

Davis AK, Barrett FS, Griffiths RR. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Context Behav Sci. (2019) 15:39–45. 10.1016/j.jcbs.2019.11.004 PubMed DOI PMC

Walsh Z, Thiessen MS. Psychedelics and the new behaviourism: considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy. Int Rev Psychiatry. (2018) 30:343–9. 10.1080/09540261.2018.1474088 PubMed DOI

Sloshower J, Guss J, Krause R, Wallace RM, Williams MT, Reed S, et al. . Psilocybin-assisted therapy of major depressive disorder using acceptance and commitment therapy as a therapeutic frame. J Context Behav Sci. (2020) 15:12–9. 10.1016/j.jcbs.2019.11.002 DOI

Stemme A, Deco G, Busch A. The neuronal dynamics underlying cognitive flexibility in set shifting tasks. J Comput Neurosci. (2007) 23:313. 10.1007/s10827-007-0034-x PubMed DOI

Tchanturia K, Davies H, Roberts M, Harrison A, Nakazato M, Schmidt U, et al. . Poor cognitive flexibility in eating disorders: examining the evidence using the Wisconsin Card Sorting Task. PLoS ONE. (2012) 7:e28331. 10.1371/journal.pone.0028331 PubMed DOI PMC

Kanen JW, Ersche KD, Fineberg NA, Robbins TW, Cardinal RN. Computational modelling reveals contrasting effects on reinforcement learning and cognitive flexibility in stimulant use disorder and obsessive-compulsive disorder: remediating effects of dopaminergic D2/3 receptor agents. Psychopharmacology. (2019) 236:2337–58. 10.1007/s00213-019-05325-w PubMed DOI PMC

Davis RN, Nolen-Hoeksema S. Cognitive inflexibility among ruminators and nonruminators. Cognit Ther Res. (2000) 24:699–711. 10.1023/A:1005591412406 DOI

Tchanturia K, Harrison A, Davies H, Roberts M, Oldershaw A, Nakazato M, et al. . Cognitive flexibility and clinical severity in eating disorders. PLoS ONE. (2011) 6:e20462. 10.1371/journal.pone.0020462 PubMed DOI PMC

Lee JK, Orsillo SM. Investigating cognitive flexibility as a potential mechanism of mindfulness in generalized anxiety disorder. J Behav Ther Exp Psychiatry. (2014) 45:208–16. 10.1016/j.jbtep.2013.10.008 PubMed DOI

Van Eylen L, Boets B, Steyaert J, Evers K, Wagemans J, Noens I. Cognitive flexibility in autism spectrum disorder: explaining the inconsistencies? Res Autism Spectr Disord. (2011) 5:1390–401. 10.1016/j.rasd.2011.01.025 DOI

Hirt ER, Devers EE, Mccrea SM. I want to be creative: exploring the role of hedonic contingency theory in the positive mood-cognitive flexibility link. J Pers Soc Psychol. (2008) 94:214. 10.1037/0022-3514.94.2.94.2.214 PubMed DOI

Pokorny T, Duerler P, Seifritz E, Vollenweider FX, Preller KH. LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making. Psychol Med. (2019) 50:2255–64. 10.1017/S0033291719002393 PubMed DOI

Kanen J, Robbins T, Carhart-Harris R, Den Ouden H. Effects of lysergic acid dyethylamide (LSD) on probabilistic reversal learning in humans. In: Summer Meeting of the British Association For Psychopharmacology (2019).

Nichols DE. Psychedelics. Pharmacol Rev. (2016) 68:264–355. 10.1124/pr.115.011478 PubMed DOI PMC

Puglisi-Allegra S, Andolina D. Serotonin and stress coping. Behav Brain Res. (2015) 277:58–67. 10.1016/j.bbr.2014.07.052 PubMed DOI

Audenaert K, Van Laere K, Dumont F, Vervaet M, Goethals I, Slegers G, et al. . Decreased 5-HT2a receptor binding in patients with anorexia nervosa. J Nuclear Med. (2003) 44:163–9. PubMed

Bailer UF, Price JC, Meltzer CC, Mathis CA, Frank GK, Weissfeld L, et al. . Altered 5-HT 2A receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness. Neuropsychopharmacology. (2004) 29:1143–55. 10.1038/sj.npp.1300430 PubMed DOI PMC

Frank GK, Kaye WH, Meltzer CC, Price JC, Greer P, Mcconaha C, et al. . Reduced 5-HT2A receptor binding after recovery from anorexia nervosa. Biol Psychiatry. (2002) 52:896–906. 10.1016/S0006-3223(02)01378-1 PubMed DOI

Tchanturia K, Anderluh MB, Morris RG, Rabe-Hesketh S, Collier DA, Sanchez P, et al. . Cognitive flexibility in anorexia nervosa and bulimia nervosa. J Int Neuropsychol Soc. (2004) 10:513. 10.1017/S1355617704104086 PubMed DOI

Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. . Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. (2006) 20:389–409. 10.2165/00023210-200620050-00004 PubMed DOI

Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. . Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. (2014) 383:533–40. 10.1016/S0140-6736(13)62106-6 PubMed DOI

Ballard C, Creese B, Gatt A, Doherty P, Francis P, Whitfield D, et al. . Identifying Novel candidates for re-purposing as potential therapeutic agents for Alzheimer's disease. bioRxiv. (2019) 25:159–170. 10.1101/622308 DOI

Garay RP, Bourin M, De Paillette E, Samalin L, Hameg A, Llorca P-M. Potential serotonergic agents for the treatment of schizophrenia. Expert Opin Investig Drugs. (2016) 25:159–70. 10.1517/13543784.2016.1121995 PubMed DOI

Carhart-Harris R, Nutt D. Serotonin and brain function: a tale of two receptors. J Psychopharmacol. (2017) 31:1091–120. 10.1177/0269881117725915 PubMed DOI PMC

Bayne T, Carter O. Dimensions of consciousness and the psychedelic state. Neurosci Conscious. (2018) 2018:niy008. 10.1093/nc/niy008 PubMed DOI PMC

Lieberman JN. Playfulness and divergent thinking: an investigation of their relationship at the kindergarten level. J Genet Psychol. (1965) 107:219–24. 10.1080/00221325.1965.10533661 PubMed DOI

Dreu CKD, Nijstad BA, Baas M. Behavioral activation links to creativity because of increased cognitive flexibility. Soc Psychol Personal Sci. (2011) 2:72–80. 10.1177/1948550610381789 DOI

Hayes S. A Liberated Mind: The essential guide to ACT. London: Random House; (2019).

Kenett YN, Levy O, Kenett DY, Stanley HE, Faust M, Havlin S. Flexibility of thought in high creative individuals represented by percolation analysis. Proc Natl Acad Sci. (2018) 115:867–72. 10.1073/pnas.1717362115 PubMed DOI PMC

Stein MI. Creativity and culture. J Psychol. (1953) 36:311–22. 10.1080/00223980.1953.9712897 DOI

Forgeard MJ, Elstein JG. Advancing the clinical science of creativity. Front Psychol. (2014) 5:613. 10.3389/fpsyg.2014.00613 PubMed DOI PMC

Blake A, Palmisano S. Divergent thinking influences the perception of ambiguous visual illusions. Perception. (2021) 50:418–37. 10.1177/03010066211000192 PubMed DOI

Harman WW, Mckim RH, Mogar RE, Fadiman J, Stolaroff MJ. Psychedelic agents in creative problem-solving: a pilot study. Psychol Rep. (1966) 19:211–27. 10.2466/pr0.1966.19.1.211 PubMed DOI

Sweat NW, Bates LW, Hendricks PS. The associations of naturalistic classic psychedelic use, mystical experience, and creative problem solving. J Psychoactive Drugs. (2016) 48:344–50. 10.1080/02791072.2016.1234090 PubMed DOI

Kuypers K, Riba J, De La Fuente Revenga M, Barker S, Theunissen E, Ramaekers J. Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacology. (2016) 233:3395–403. 10.1007/s00213-016-4377-8 PubMed DOI PMC

Germann CB. 5-methoxy-N, N-dimethyltryptamine: an ego-dissolving endogenous neurochemical catalyst of creativity. Act Nerv Super. (2019) 61:170–216. 10.1007/s41470-019-00063-y DOI

Sessa B. Is it time to revisit the role of psychedelic drugs in enhancing human creativity? J Psychopharmacol. (2008) 22:821–7. 10.1177/0269881108091597 PubMed DOI

Baggott MJ. Psychedelics and creativity: a review of the quantitative literature. PeerJ PrePrints. (2015) 3:e1202ve1201. 10.7287/peerj.preprints.1202v1 DOI

Girn M, Mills C, Roseman L, Carhart-Harris RL, Christoff K. Updating the dynamic framework of thought: Creativity and psychedelics. Neuroimage. (2020) 213:116726. 10.1016/j.neuroimage.2020.116726 PubMed DOI

Mccrae RR. Creativity, divergent thinking, and openness to experience. J Pers Soc Psychol. (1987) 52:1258. 10.1037/0022-3514.52.6.1258 DOI

Chen X, He J, Fan X. Relationships between openness to experience, cognitive flexibility, self-esteem, and creativity among bilingual college students in the US. Int J Bilingual Educ Bilingualism. (2019) 1–13. 10.1080/13670050.2019.1688247 DOI

Costa PT, McCrae RR. The revised NEO personality inventory (NEO-PI-R). The SAGE Handbook Pers Theory Assess. (2008) 2:179–98. 10.4135/9781849200479.n9 DOI

Carhart-Harris RL, Kaelen M, Bolstridge M, Williams T, Williams L, Underwood R, et al. . The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. (2016) 46:1379–90. 10.1017/S0033291715002901 PubMed DOI

Erritzoe D, Smith J, Fisher PM, Carhart-Harris R, Frokjaer VG, Knudsen GM. Recreational use of psychedelics is associated with elevated personality trait openness: exploration of associations with brain serotonin markers. J Psychopharmacol. (2019) 33:1068–75. 10.1177/0269881119827891 PubMed DOI

Wagner MT, Mithoefer MC, Mithoefer AT, Macaulay RK, Jerome L, Yazar-Klosinski B, et al. . Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. J Psychopharmacol. (2017) 31:967–74. 10.1177/0269881117711712 PubMed DOI PMC

Eldesouky L. Openness to experience and health: a review of the literature. Yale Rev Undergrad Res Psychol. (2012) 5:24–42.

Bishop SR, Lau M, Shapiro S, Carlson L, Anderson ND, Carmody J, et al. . Mindfulness: a proposed operational definition. Clin Psychol: Sci Pract. (2004) 11:230–41. 10.1093/clipsy.bph077 DOI

Baer RA, Smith GT, Lykins E, Button D, Krietemeyer J, Sauer S, et al. . Construct validity of the five facet mindfulness questionnaire in meditating and nonmeditating samples. Assessment. (2008) 15:329–42. 10.1177/1073191107313003 PubMed DOI

Hayes SC, Law S, Malady M, Zhu Z, Bai X. The centrality of sense of self in psychological flexibility processes: what the neurobiological and psychological correlates of psychedelics suggest. J Context Behav Sci. (2019) 15:30–8. 10.1016/j.jcbs.2019.11.005 DOI

Speth J, Speth C, Kaelen M, Schloerscheidt AM, Feilding A, Nutt DJ, et al. . Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. J Psychopharmacol. (2016) 30:344–53. 10.1177/0269881116628430 PubMed DOI

Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. (2018) 8:974. 10.3389/fphar.2017.00974 PubMed DOI PMC

Haijen ECHM, Kaelen M, Roseman L, Timmermann C, Russ S, Nutt D, et al. . Predicting responses to psychedelics: a prospective study. Front Pharmacol. (2018) 9:897. 10.3389/fphar.2018.00897 PubMed DOI PMC

Schmid Y, Liechti ME. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology. (2018) 235:535–45. 10.1007/s00213-017-4733-3 PubMed DOI PMC

Lebedev AV, Kaelen M, Lövdén M, Nilsson J, Feilding A, Nutt DJ, et al. . LSD-induced entropic brain activity predicts subsequent personality change. Hum Brain Mapp. (2016) 37:3203–13. 10.1002/hbm.23234 PubMed DOI PMC

Lifshitz M, Van Elk M, Luhrmann T. Absorption and spiritual experience: A review of evidence and potential mechanisms. Conscious Cogn. (2019) 73:102760. 10.1016/j.concog.2019.05.008 PubMed DOI

Maclean KA, Leoutsakos JMS, Johnson MW, Griffiths RR. Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig. (2012) 51:721–37. 10.1111/j.1468-5906.2012.01685.x PubMed DOI PMC

Lukoff D, Lu F, Turner R. From spiritual emergency to spiritual problem: the transpersonal roots of the new DSM-IV category. J Hum Psychol. (1998) 38:21–50. 10.1177/00221678980382003 DOI

Stace WT. Mysticism and Philosophy. Philadelphia, PA: J. B. Lippincott; (1960).

Petri G, Expert P, Turkheimer F, Carhart-Harris R, Nutt D, Hellyer PJ, et al. . Homological scaffolds of brain functional networks. J R Soc Interface. (2014) 11:20140873. 10.1098/rsif.2014.0873 PubMed DOI PMC

Millière R, Carhart-Harris RL, Roseman L, Trautwein F-M, Berkovich-Ohana A. Psychedelics, meditation, and self-consciousness. Front Psychol. (2018) 9:1475. 10.3389/fpsyg.2018.01475 PubMed DOI PMC

Nielson EM, May DG, Forcehimes AA, Bogenschutz MP. The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions. Front Pharmacol. (2018) 9:132. 10.3389/fphar.2018.00132 PubMed DOI PMC

Tagliazucchi E, Roseman L, Kaelen M, Orban C, Muthukumaraswamy SD, Murphy K, et al. . Increased global functional connectivity correlates with LSD-induced ego dissolution. Curr Biol. (2016) 26:1043–50. 10.1016/j.cub.2016.02.010 PubMed DOI

Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, et al. . Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci USA. (2016) 113:4853–8. 10.1073/pnas.1518377113 PubMed DOI PMC

Hanh TN. The Heart of Buddha's Teaching. London: Random House; (2008).

Edgerton F. The Bhagavad Gita. Cambridge: Harvard University Press; (1972).

Girn M, Roseman L, Bernhardt B, Smallwood J, Carhart-Harris RL, Spreng N. LSD flattens the functional hierarchy of the human brain. bioRxiv. (2020). 10.1101/2020.05.01.072314 DOI

Atasoy S, Roseman L, Kaelen M, Kringelbach ML, Deco G, Carhart-Harris RL. Connectome-harmonic decomposition of human brain activity reveals dynamical repertoire re-organization under LSD. Sci Rep. (2017) 7:17661. 10.1038/s41598-017-17546-0 PubMed DOI PMC

Tagliazucchi E, Carhart-Harris R, Leech R, Nutt D, Chialvo DR. Enhanced repertoire of brain dynamical states during the psychedelic experience. Hum Brain Mapp. (2014) 35:5442–56. 10.1002/hbm.22562 PubMed DOI PMC

Atasoy S, Vohryzek J, Deco G, Carhart-Harris RL, Kringelbach ML. Common neural signatures of psychedelics: frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition. Prog Brain Res. (2018) 242:97–120. 10.1016/bs.pbr.2018.08.009 PubMed DOI

Lord LD, Expert P, Atasoy S, Roseman L, Rapuano K, Lambiotte R, et al. . Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin. Neuroimage. (2019) 199:127–42. 10.1016/j.neuroimage.2019.05.060 PubMed DOI

Roseman L, Leech R, Feilding A, Nutt DJ, Carhart-Harris RL. The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Front Hum Neurosci. (2014) 8:204. 10.3389/fnhum.2014.00204 PubMed DOI PMC

Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology. (2008) 33:88. 10.1038/sj.npp.1301574 PubMed DOI

Cramer SC, Sur M, Dobkin BH, O'brien C, Sanger TD, Trojanowski JQ, et al. . Harnessing neuroplasticity for clinical applications. Brain. (2011) 134:1591–609. 10.1093/brain/awr039 PubMed DOI PMC

Doidge N. The Brain That Changes Itself: Stories of Personal Triumph From the Frontiers of Brain Science. Penguin: (2007).

Stam CJ. Modern network science of neurological disorders. Nat Rev Neurosci. (2014) 15:683. 10.1038/nrn3801 PubMed DOI

Lydon-Staley D, Kuehner C, Zamoscik V, Huffziger S, Kirsch P, Bassett D. Repetitive negative thinking in daily life and functional connectivity among default mode, fronto-parietal, and salience networks. Transl Psychiatry. (2019) 9:1–12. 10.1038/s41398-019-0560-0 PubMed DOI PMC

Zheng H, Li F, Bo Q, Li X, Yao L, Yao Z, et al. . The dynamic characteristics of the anterior cingulate cortex in resting-state fMRI of patients with depression. J Affect Disord. (2018) 227:391–7. 10.1016/j.jad.2017.11.026 PubMed DOI

Kolassa I-T, Elbert T. Structural and functional neuroplasticity in relation to traumatic stress. Curr Dir Psychol Sci. (2007) 16:321–5. 10.1111/j.1467-8721.2007.00529.x DOI

Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. (2018) 23:801. 10.1038/mp.2017.255 PubMed DOI PMC

Cavus I, Duman RS. Influence of estradiol, stress, and 5-HT2A agonist treatment on brain-derived neurotrophic factor expression in female rats. Biol Psychiatry. (2003) 54:59–69. 10.1016/S0006-3223(03)00236-1 PubMed DOI

Olson DE. Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics. J Exp Neurosci. (2018) 12:1179069518800508. 10.1177/1179069518800508 PubMed DOI PMC

Jefsen OH, Elfving B, Wegener G, Müller HK. Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin. J Psychopharmacol. (2020) 35:483–93. 10.1177/0269881120959614 PubMed DOI

Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry. (2017) 4:409–18. 10.1016/S2215-0366(17)30015-9 PubMed DOI PMC

Hölzel BK, Lazar SW, Gard T, Schuman-Olivier Z, Vago DR, Ott U. How does mindfulness meditation work? Proposing mechanisms of action from a conceptual and neural perspective. Perspect Psychol Sci. (2011) 6:537–59. 10.1177/1745691611419671 PubMed DOI

Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuroendocrinol Let. (2013) 34:287–93. PubMed

Luckenbaugh DA, Niciu MJ, Ionescu DF, Nolan NM, Richards EM, Brutsche NE, et al. . Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord. (2014) 159:56–61. 10.1016/j.jad.2014.02.017 PubMed DOI PMC

Olson DE. The Subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol Trans Sci. (2020) 4:563–7. 10.1021/acsptsci.0c00192 PubMed DOI PMC

Vaidya VA, Marek GJ, Aghajanian GK, Duman RS. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci. (1997) 17:2785–95. 10.1523/JNEUROSCI.17-08-02785.1997 PubMed DOI PMC

Vaidya V, Castro M, Pei Q, Sprakes M, Grahame-Smith D. Influence of thyroid hormone on 5-HT1A and 5-HT2A receptor-mediated regulation of hippocampal BDNF mRNA expression. Neuropharmacology. (2001) 40:48–56. 10.1016/S0028-3908(00)00094-0 PubMed DOI

Morales-García JA, De La Fuente Revenga M, Alonso-Gil S, Rodríguez-Franco MI, Feilding A, Perez-Castillo A, et al. . The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro. Sci Rep. (2017) 7:5309. 10.1038/s41598-017-05407-9 PubMed DOI PMC

Xing L, Kalebic N, Namba T, Vaid S, Wimberger P, Huttner WB. Serotonin receptor 2A activation promotes evolutionarily relevant basal progenitor proliferation in the developing neocortex. Neuron. (2020) 108:1113–29.e6. 10.1016/j.neuron.2020.09.034 PubMed DOI

Vicenzi S, Foa L, Gasperini RJ. Serotonin functions as a bidirectional guidance molecule regulating growth cone motility. Cell Mol Life Sci. (2021) 78:2247–62. 10.1007/s00018-020-03628-2 PubMed DOI PMC

Dewitt TJ, Sih A, Wilson DS. Costs and limits of phenotypic plasticity. Trends Ecol Evol. (1998) 13:77–81. 10.1016/S0169-5347(97)01274-3 PubMed DOI

Branchi I. The double edged sword of neural plasticity: increasing serotonin levels leads to both greater vulnerability to depression and improved capacity to recover. Psychoneuroendocrinology. (2011) 36:339–51. 10.1016/j.psyneuen.2010.08.011 PubMed DOI

Schartner MM, Carhart-Harris RL, Barrett AB, Seth AK, Muthukumaraswamy SD. Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. Sci Rep. (2017) 7:46421. 10.1038/srep46421 PubMed DOI PMC

Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, et al. . Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci. (2012) 109:2138–43. 10.1073/pnas.1119598109 PubMed DOI PMC

Carhart-Harris RL, Leech R, Hellyer PJ, Shanahan M, Feilding A, Tagliazucchi E, et al. . The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci. (2014) 8:20. 10.3389/fnhum.2014.00020 PubMed DOI PMC

Nutt D, Erritzoe D, Carhart-Harris R. Psychedelic psychiatry's brave new world. Cell. (2020) 181:24–8. 10.1016/j.cell.2020.03.020 PubMed DOI

Carhart-Harris RL. The entropic brain-revisited. Neuropharmacology. (2018) 142:167–78. 10.1016/j.neuropharm.2018.03.010 PubMed DOI

Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, et al. . Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. (2017) 7:13187. 10.1038/s41598-017-13282-7 PubMed DOI PMC

Beliveau V, Ganz M, Feng L, Ozenne B, Højgaard L, Fisher PM, et al. . A high-resolution in vivo atlas of the human brain's serotonin system. J Neurosci. (2017) 37:120–8. 10.1523/JNEUROSCI.2830-16.2016 PubMed DOI PMC

Van Laarhoven PJ, Aarts EH. Simulated Annealing. Simulated Annealing: Theory and Applications. Heidelberg: Springer Netherlands; (1987).

Olthof M, Hasselman F, Strunk G, Aas B, Schiepek G, Lichtwarck-Aschoff A. Destabilization in self-ratings of the psychotherapeutic process is associated with better treatment outcome in patients with mood disorders. Psychother Res. (2019) 30:520–31. 10.1080/10503307.2019.1633484 PubMed DOI

Crown S. Contraindications and dangers of psychotherapy. Br J Psychiatry. (1983) 143:436–41. 10.1192/bjp.143.5.436 PubMed DOI

Lloyd V. The Jarisch-Herxheimer reaction. Br J Venereal Dis. (1945) 21:42. 10.1136/sti.21.1.42 PubMed DOI PMC

Russ SL, Carhart-Harris R, Maruyama G, Elliott M. Replication and extension of a model predicting response to psilocybin. Psychopharmacology. (2019) 236:3221–30. 10.1007/s00213-019-05279-z PubMed DOI

Strogatz SH. Nonlinear Dynamics and Chaos With Student Solutions Manual: With Applications to Physics, Biology, Chemistry, and Engineering. CRC Press; (2018).

Grencavage LM, Norcross JC. Where are the commonalities among the therapeutic common factors? Prof Psychol Res Pract. (1990) 21:372. 10.1037/0735-7028.21.5.372 DOI

Alamia A, Timmermann C, Vanrullen R, Carhart-Harris RL. DMT alters cortical travelling waves. Elife. (2020) e59784. 10.7554/eLife.59784 PubMed DOI PMC

Cameron JL, Eagleson KL, Fox NA, Hensch TK, Levitt P. Social origins of developmental risk for mental and physical illness. J Neurosci. (2017) 37:10783–91. 10.1523/JNEUROSCI.1822-17.2017 PubMed DOI PMC

Ismail FY, Fatemi A, Johnston MV. Cerebral plasticity: windows of opportunity in the developing brain. Eur J Paediatr Neurol. (2017) 21:23–48. 10.1016/j.ejpn.2016.07.007 PubMed DOI

Jayawickreme E, Blackie LE. Post-traumatic growth as positive personality change: evidence, controversies and future directions. Eur J Pers. (2014) 28:312–31. 10.1002/per.1963 DOI

Boykin DM, Anyanwu J, Calvin K, Orcutt HK. The moderating effect of psychological flexibility on event centrality in determining trauma outcomes. Psychol Trauma Theory Res Pract Policy. (2019) 12:193–9. 10.1037/tra0000490 PubMed DOI

Buckner RL, Krienen FM. The evolution of distributed association networks in the human brain. Trends Cogn Sci. (2013) 17:648–65. 10.1016/j.tics.2013.09.017 PubMed DOI

Rilling JK. Comparative primate neuroimaging: insights into human brain evolution. Trends Cogn Sci. (2014) 18:46–55. 10.1016/j.tics.2013.09.013 PubMed DOI

Baldassano C, Chen J, Zadbood A, Pillow JW, Hasson U, Norman KA. Discovering Event structure in continuous narrative perception and memory. Neuron. (2017) 95:709–21.e5. 10.1016/j.neuron.2017.06.041 PubMed DOI PMC

Huth AG, De Heer WA, Griffiths TL, Theunissen FE, Gallant JL. Natural speech reveals the semantic maps that tile human cerebral cortex. Nature. (2016) 532:453–8. 10.1038/nature17637 PubMed DOI PMC

Sepulcre J, Liu H, Talukdar T, Martincorena I, Yeo BT, Buckner RL. The organization of local and distant functional connectivity in the human brain. PLoS Comput Biol. (2010) 6:e1000808. 10.1371/journal.pcbi.1000808 PubMed DOI PMC

Margulies DS, Ghosh SS, Goulas A, Falkiewicz M, Huntenburg JM, Langs G, et al. . Situating the default-mode network along a principal gradient of macroscale cortical organization. Proc Natl Acad Sci USA. (2016) 113:12574–9. 10.1073/pnas.1608282113 PubMed DOI PMC

Krienen FM, Yeo BT, Ge T, Buckner RL, Sherwood CC. Transcriptional profiles of supragranular-enriched genes associate with corticocortical network architecture in the human brain. Proc Natl Acad Sci USA. (2016) 113:E469–78. 10.1073/pnas.1510903113 PubMed DOI PMC

Xu T, Nenning KH, Schwartz E, Hong SJ, Vogelstein JT, Goulas A, et al. . Cross-species functional alignment reveals evolutionary hierarchy within the connectome. Neuroimage. (2020) 223:117346. 10.1016/j.neuroimage.2020.117346 PubMed DOI PMC

Vaishnavi SN, Vlassenko AG, Rundle MM, Snyder AZ, Mintun MA, Raichle ME. Regional aerobic glycolysis in the human brain. Proc Natl Acad Sci. (2010) 107:17757–62. 10.1073/pnas.1010459107 PubMed DOI PMC

Vlassenko AG, Vaishnavi SN, Couture L, Sacco D, Shannon BJ, Mach RH, et al. . Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ) deposition. Proc Natl Acad Sci. (2010) 107:17763–7. 10.1073/pnas.1010461107 PubMed DOI PMC

Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Trans Sci. (2020) 4:568–72. 10.1021/acsptsci.0c00194 PubMed DOI PMC

Szigeti B, Kartner L, Blemings A, Rosas F, Feilding A, Nutt DJ, et al. . Self-blinding citizen science to explore psychedelic microdosing. Elife. (2021) 10:e62878. 10.7554/eLife.62878 PubMed DOI PMC

Kaertner L, Steinborn M, Kettner H, Spriggs M, Roseman L, Buchborn T, et al. . Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Sci Rep. (2021) 11:1–11. 10.1038/s41598-021-81446-7 PubMed DOI PMC

Starfield B, Hyde J, Gérvas J, Heath I. The concept of prevention: a good idea gone astray? J Epidemiol Commun Health. (2008) 62:580–3. 10.1136/jech.2007.071027 PubMed DOI

Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. (2008) 22:603–20. 10.1177/0269881108093587 PubMed DOI PMC

Martinotti G, Santacroce R, Pettorruso M, Montemitro C, Spano MC, Lorusso M, et al. . Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci. (2018) 8:47. 10.3390/brainsci8030047 PubMed DOI PMC

Eisner B. Set, setting, and matrix. J Psychoact Drugs. (1997) 29:213–6. 10.1080/02791072.1997.10400190 PubMed DOI

Hartogsohn I. Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol. (2016) 30:1259–67. 10.1177/0269881116677852 PubMed DOI

Van de Cruys S, Evers K, Van Der Hallen R, Van Eylen L, Boets B, De-Wit L, et al. . Precise minds in uncertain worlds: predictive coding in autism. Psychol Rev. (2014) 121:649. 10.1037/a0037665 PubMed DOI

Van de Cruys S, Van Der Hallen R, Wagemans J. Disentangling signal and noise in autism spectrum disorder. Brain Cogn. (2017) 112:78–83. 10.1016/j.bandc.2016.08.004 PubMed DOI

Tyndall I, Waldeck D, Pancani L, Whelan R, Roche B, Dawson DL. The acceptance and action questionnaire-II (AAQ-II) as a measure of experiential avoidance: concerns over discriminant validity. J Context Behav Sci. (2018) 12:278–84. 10.1016/j.jcbs.2018.09.005 DOI

Wolgast M. What does the acceptance and action questionnaire (AAQ-II) really measure? Behav Ther. (2014) 45:831–9. 10.1016/j.beth.2014.07.002 PubMed DOI

Ford I, Norrie J. Pragmatic trials. New Engl J Med. (2016) 375:454–63. 10.1056/NEJMra1510059 PubMed DOI

Mullins CD, Vandigo J, Zheng Z, Wicks P. Patient-centeredness in the design of clinical trials. Value Health. (2014) 17:471–5. 10.1016/j.jval.2014.02.012 PubMed DOI PMC

Carhart-Harris RL, Wagner AC, Agrawal M, Kettner H, Rosenbaum JF, Gazzaley A, et al. . Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine? J Psychopharmacol. (2021). 10.1177/02698811211008567 PubMed DOI PMC

Wolff M, Evens R, Mertens LJ, Koslowski M, Betzler F, Gründer G, et al. . Learning to Let Go: A cognitive-behavioral model of how psychedelic therapy promotes acceptance. Front Psychiatry. (2020) 11:5. 10.3389/fpsyt.2020.00005 PubMed DOI PMC

Mackewn J. Developing Gestalt Counseling. Newbury Park: Sage; (1997).

Gabbard GO, Litowitz BE, Williams P. Textbook of Psychoanalysis. Washington: American Psychiatric Pub. (2012).

Wade DT, Halligan PW. The Biopsychosocial Model of Illness: A Model Whose Time Has Come. London, England: SAGE Publications Sage UK; (2017). PubMed

Global Adversities, the Media, and Mental Health